Cabergoline 1 MG

DRUG3 trials

Sponsors

Stanford University, Aarhus University Hospital

Conditions

Lactation SuppressedMigraine

Phase 2

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

CompletedNCT04701333

Stanford UniversityLactation Suppressed

Start: 2021-04-01End: 2023-03-01Updated: 2024-02-13

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

CompletedNCT06029673

Stanford UniversityLactation Suppressed

Start: 2024-02-07End: 2025-07-01Updated: 2025-10-03

Cabergoline for Episodic Migraine

RecruitingNCT07072910

Aarhus University HospitalMigraine

Start: 2025-11-12End: 2028-09-01Target: 150Updated: 2025-11-18

Related Papers

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial.

2025-12-05

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss

Obstetrics and Gynecology2023-05-0314 citations